Company
Headquarters: London, United Kingdom
Employees: 12
CEO: Mr. Peter John Harrison MA
£162.9 Million
GBP as of Jan. 1, 2025
US$204.4 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £13.6 M |
| EBITDA | £10.3 M |
| Gross Profit TTM | £12.0 M |
| Profit Margin | 63.73% |
| Operating Margin | 77.28% |
| Quarterly Revenue Growth | 13.20% |
Bioventix plc has the following listings and related stock indices.
Stock: LSE: BVXP wb_incandescent
Stock: FSX: 51B wb_incandescent